



UNIVERSITAS
GADJAH MADA

Sharing Session Probiotik

Endang Sutriswati Rahayu

Mifta Gatya

PUIPT – Probiotik, Pusat Studi Pangan dan Gizi,

Universitas Gadjah Mada

21 Juli 2025

Garis Besar Pelaksanaan Uji Klinis



UNIVERSITAS GADJAH MADA

- Memperoleh dokumen etik
- Rekrutment subjek sesuai dengan kriteria inklusi

- Pada hari pertama setelah tahap pembiasaan, subjek diminta untuk mengumpulkan feses dan pemeriksaan parameter klinis



- Sosialisasi kegiatan penelitian
- Penandatanganan informed consent bagi yang bersedia berpartisipasi sebagai subjek
- Pengisian kuisisioner skrining
- Pengukuran parameter klinis (sesuai dengan parameter pada *study design*)
- Subjek diminta untuk tidak mengonsumsi produk probiotik lain serta antibiotik selama penelitian berlangsung
- Menjalankan tahap pembiasaan (baseline)

- a. Blinding dan Randomization (double blind study)
- b. Melakukan visit penelitian secara berkala untuk melakukan:
 - Pembagian produk
 - Pengukuran parameter klinis subjek
 - Pembagian kuisisioner catatan harian berisi konsumsi produk, konsumsi produk probiotik dan prebiotik, aktivitas fisik, catatan Kesehatan, konsumsi obat, dan catatan pola makan, frekuensi BAB dan kualitasnya

Independent Variable

Produk untuk kelompok probiotik

Produk untuk kelompok placebo:
menerima produk yang sama
tanpa penambahan probiotik

Kualitas feses

pH feses

Jumlah koloni
probiotik

Dependent Variable

Jumlah sel masing-masing
bakteri probiotik

Parameter penelitian lainnya

- Frekuensi BAB
- Pola makan subjek
- Kondisi kesehatan dan konsumsi obat

Kit Koleksi Sampel Feses



UNIVERSITAS GADJAH MADA

Thermo Bag



Digunakan untuk membawa sampel feses – stabil terhadap suhu

Pack



Masker

: Untuk mencegah kontaminasi dan bau dari feses

Sarung tangan

: Untuk menghindari kontaminasi dari tangan subjek


Kertas steril

: Alas untuk meletakkan feses

Botol feses 1



Botol feses 2



Botol feses 3*



Anaerobe pouch*



Zipper pouch*



Ice gel (6 pcs)



Terdapat RNA later dan *glass bead*

Untuk analisa qPCR

Botol kosong

Untuk analisa *culture methode*

Botol kosong

Untuk analisa *culture methode*

Untuk kondisi anaerobik

Untuk pouch botol feses 3 dan oxygen absorber

Rendam dalam air, letakkan di freezer – pengganti es batu sementara

NB: tanda (*) menunjukkan bahwa perlengkapan tersebut hanya digunakan apabila karakter bakteri adalah anaerob obligat



Tata Cara Sampling Feses

1. Rendam ice gel ke dalam baskom berisi air. Pastikan ice gel sudah mengembang, kemudian masukkan ice gel ke dalam freezer.
2. Apabila sudah akan buang air besar, gunakan masker, sarung tangan dan pasang kertas steril pada ujung-ujung toilet. Pastikan bahwa yang tertampung pada kertas steril hanya feses saja tanpa ada air seni ataupun air toilet
3. Ambil feses yang tertampung pada kertas steril di 3 titik menggunakan sendok yang ada pada botol feses 1. Pastikan RNA later dan glass bead pada botol feses tidak tumpah.
4. Pastikan sampel feses tercampur seluruhnya pada RNA later dan tutup dengan rapat.
5. Ambil botol feses 2 dan masukkan feses hingga 2/3 penuh menggunakan sendok yang ada pada botol, kemudian tutup rapat.
- 6. Ambil botol feses 3, masukkan feses hingga 2/3 penuh menggunakan sendok yang ada pada botol.**
- 7. Buka zipper pouch, kemudian masukkan botol feses 3 dalam kondisi sedikit terbuka ke dalam zipper pouch.**
- 8. Segera buka anaerob pouch, ambil kantong yang ada di dalam pouch dan masukkan ke dalam zipper pouch.**
- 9. Sebelum zipper ditutup, tekan dari bagian bawah hingga ke atas untuk mengeluarkan udara yang ada di dalam zipper pouch, kemudian tutup zipper dengan rapat**
10. Masukkan botol feses 1,2, dan 3, lalu masukkan ice gel yang sudah jadi ke dalam *thermo bag*.

NB: Tahap 6-9 hanya dilakukan jika terdapat bakteri anaerob obligat



Pembagian *Sampling Kit*

- *Sampling kit* dibagikan dengan melakukan penjelasan langsung cara sampling kepada subjek **satu per satu** hingga cara treatment untuk sampel hingga sampel sampai ke tangan peneliti
- Sediakan video cara sampling feses

Penanganan dan Pengiriman Sampel



- Sampel feses sudah siap dikirim
- Subjek menghubungi peneliti




Sampel feses dikirim menggunakan aplikasi "GOJEK" langsung setelah feses sudah siap kirim



Diterima dalam kondisi baik oleh tim peneliti dalam waktu 30 menit



Feses untuk *culture methode* segera di plating setelah sampai




Sample untuk qPCR ditimbang, dihomogenisasi dan disimpan dalam *deep freeze* (-80 °C) sebelum di analisa


Uji koloni pada Culture Methods




UNIVERSITAS GADJAH MADA



Koloni BAL pada media MRS



Koloni *L. plantarum*
pada media LPSM



Koloni *Bifidobacterium*
Pada media BSM

Uji koloni pada Culture Methods



UNIVERSITAS GADJAH MADA

- Tujuan uji ini adalah untuk menentukan kemampuan masing-masing strain hidup di feses – dengan menguji beberapa koloni yang ada di culture methods (diambil secara acak) – dilakukan analisis PCR menggunakan primer BOX-A1R bersama dengan strain probiotik
- Primer BOX-A1R - 5'-CTACGGCAAGGCGACGCTGACG-3'.
- Masing-masing strain akan memiliki pola pita yang spesifik
- Apabila koloni dari culture method memiliki pola spesifik yang sama dengan strain murni probiotik – berarti strain probiotik tsb dapat berkoloni (hidup) dalam usus




Figure 1. Result of REP-PCR using BOX A1R primers. 1- *L. plantarum* Mut-7; 2- *L. plantarum* Mut-7 20x dilution; 3- *L. plantarum* Dad13; 4- *L. plantarum* Mut-13; 5- *L. plantarum* Mut-13 20x dilution; M: Molecular weight markers (100-3000 bp). (sumber author/ESR)
BOX A1R Primer:
(5'CTACGGCAAGGCGACGCTGACGCTGACG-3')



FEMS Microbiology Letters 205 (2001) 31–36





www.fems-microbiology.org

Applicability of rep-PCR fingerprinting for identification of *Lactobacillus* species

Dirk Gevers^{a,*}, Geert Huys^a, Jean Swings^{a,b}

^a Laboratory of Microbiology, Department of Biochemistry, Physiology and Microbiology, Ghent University, K.L. Ledeganckstraat 35, 9000 Gent, Belgium

^b BCCM/TM/LMG Bacteria Collection, Department of Biochemistry, Physiology and Microbiology, Ghent University, K.L. Ledeganckstraat 35, 9000 Gent, Belgium



LMG 13087 ^T	B	<i>Lactobacillus paracasei</i> subsp. <i>paracasei</i>
LMG 1284	B	<i>Lactobacillus plantarum</i>
LMG 9206	B	<i>Lactobacillus plantarum</i>
LMG 6907 ^T	B	<i>Lactobacillus plantarum</i>
LMG 18021	B	<i>Lactobacillus plantarum</i>
LMG 10755 ^T	B	<i>Lactobacillus pentosus</i>
LMG 18401	B	<i>Lactobacillus pentosus</i>
LMG 16673 ^T	B	<i>Lactobacillus paraplantarum</i>
LMG 19456	LAB	<i>Enterococcus faecalis</i>
LMG 9469 ^T	LAB	<i>Weissella halotolerans</i>

Endang S Rahayu
Pratama Nur Hasan
PSPG - UGM

Fig. 1. Dendrogram generated after cluster analysis of the digitized (GTG)₅-PCR fingerprints of the reference strains. The dendrogram was constructed using the unweighted pair-group method using arithmetic averages with correlation levels expressed as percentage values of the Pearson correlation coefficient. ^aLMG: BCCM/TM/LMG bacteria collection (Laboratory of Microbiology, Ghent University, Belgium, <http://www.belspo.be/bccm>); ^T: type strain; ^bGroup A: obligately homofermentative lactobacilli, B: facultatively heterofermentative lactobacilli, and C: obligately heterofermentative lactobacilli.

Metoda molekuler, berbasis PCR menggunakan spesifik primer dapat digunakan untuk membedakan strain pada spesies yang sama. Contohnya adalah *Lactobacillus plantarum* berbagai strain memiliki profil pita yang berbeda dari hasil amplifikasi menggunakan primer spesifik




EFFECTS OF CONSUMPTION OF FERMENTED MILK CONTAINING INDIGENOUS
PROBIOTIC *LACTOBACILLUS PLANTARUM* DAD-13 ON THE FECAL
MICROBIOTA OF HEALTHY INDONESIAN VOLUNTEERS

¹Endang S. Rahayu, ¹Muhammad N. Cahyanto, ¹Mariyatun, ²Martinus-Agus Sarwoko, ²Pri Haryono,
¹Linda Windiarti, ²Joko Sutriyanto, ³Istiti Kandarina, ⁴Sri Nurfiani, ⁴Eni Zulaichah, and ¹Tyas Utami

https://drive.google.com/file/d/1L4u6hgZ1p_ip86qWapR-fF3KKyJjU9BM/view

FIGURE 2. Changes of fecal microbiota after consumption of fermented milk containing *L. plantarum* DAD 13 for 20 days




Design study: Pre and post

Total subjects: 30 people; Consumption : 20 days

Enumeration and isolation of *L. plantarum* from fecal samples using LPSM

Result: *Lactobacillus plantarum* Dad-13 **could survive** in the colon - based on the similar profile of PCR using BOX A1R Primer of isolates from subjects fecal after consumption



Recovery and Molecular Detection of *Lactobacillus plantarum* Dad-13 from The Feces of Healthy Indonesian Volunteers After Intake of Fermented Milk

Rep-PCR using primer BOX A1R; M : Molecular weight markers (100-3000 bp); 1- F1.2; 2- F1.12; 3- F1.14; 4- F1.18; 5- F1.30; 6- *L.plantarum* Dad 13; 7- F2.1; 8- F2.12; 9- F2.14; 10- F2.18; 11- F2.30; 12- F4.2; 13- F4.12; 14- F4.14; 15- F4.18; 16- F4.30

During the 20 days of consumption (F2) of Rep - PCR results showed the same band profile among isolates from stool 3 volunteers (no 12,14,30) with *L. plantarum* Dad13
Conclusion : *L. plantarum* Dad13 can grow in the colon

- Budhwani, Z., Buragina, J. T., Lang, J., & Acedo, J. Z. (2023). Characterization of the novel leaderless bacteriocin, bawcin, from *Bacillus wiedmannii*. *International Journal of Molecular Sciences*, 24(23), 16965. <https://doi.org/10.3390/ijms242316965>
- Bujalance, C., Jiménez-Valera, M., Moreno, E., & Ruiz-Bravo, A. (2006, September). A selective differential medium for *Lactobacillus plantarum*. *Journal of Microbiological Methods*, 66(3), 572–575. <https://doi.org/10.1016/j.mimet.2006.02.005>
- Chen, X., Liu, Y., Li, L., Lei, Y., Zeng, Z., Xu, J., Li, Z., & Savino, F. (2021). Infantile colic treated with *Bifidobacterium longum* CECT7894 and *Pediococcus pentosaceus* CECT8330: A randomized, double-blind, placebo-controlled trial. *Frontiers in Pediatrics*, 9, 635176. <https://doi.org/10.3389/fped.2021.635176>
- Chen, Y., Jin, Y., Stanton, C., Ross, R. P., Wang, Z., Zhao, J., Zhang, H., Yang, B., & Chen, W. (2020). Dose-response efficacy and mechanisms of orally administered CLA-producing *Bifidobacterium breve* CCFM683 on DSS-induced colitis in mice. *Journal of Functional Foods*, 75, 104245. <https://doi.org/10.1016/j.jff.2020.104245>
- Chen, X., Chen, Y., Stanton, C., Ross, R. P., Zhao, J., Yang, B., & Chen, W. (2024). Protective effects of *Bifidobacterium breve* on imiquimod-induced psoriasis in mice through secondary bile acid production and FXR-TLR4/NF- κ B pathway. *Food Science and Human Wellness*, 13(6), 3447–3460. <https://doi.org/10.26599/FSHW.2023.9250029>
- CNIPA. (2008). Primer and method for detecting *Rhodopseudomonas palustris* (Chinese Patent CN101195841A). Retrieved from <https://patents.google.com/patent/CN101195841A/en>
- Di Lena, M., Quero, G. M., Santovito, E., Verran, J., De Angelis, M., Fusco, V., ... Santoro, A. (2015). A selective medium for isolation and accurate enumeration of *Lactobacillus casei*-group members in probiotic milks and dairy products. *International Dairy Journal*, 47, 27–36. <https://doi.org/10.1016/j.idairyj.2015.01.018>
- Dong, F., Xiao, F., Li, X., Li, Y., Wang, X., Yu, G., Zhang, T., & Wang, Y. (2022). *Pediococcus pentosaceus* CECT8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. *Journal of Translational Medicine*, 20, Article 33. <https://doi.org/10.1186/s12967-022-03235-8>
- Gao, H., Yang, B., Stanton, C., Ross, R. P., Zhang, H., Chen, Y., ... Chen, W. (2021). Linoleic acid induces different metabolic modes in two *Bifidobacterium breve* strains with different conjugated linoleic acid-producing abilities. *LWT – Food Science and Technology*, 142, 110974. <https://doi.org/10.1016/j.lwt.2021.110974>
- Griffiths, M. W., & Tellez, A. M. (2013). *Lactobacillus helveticus*: The proteolytic system. *Frontiers in Microbiology*, 4, 30. <https://doi.org/10.3389/fmicb.2013.00030>
- Hidalgo-Cantabrana, C., et al. (2014). Bile resistance mechanisms in *Bifidobacterium*. *Frontiers in Microbiology*, 5, 514. <https://doi.org/10.3389/fmicb.2014.00514>
- Jena, R., Choudhury, P. K., Puniya, A. K., & Tomar, S. K. (2021). Efficacy of BOX-PCR fingerprinting for taxonomic discrimination of bifidobacterial species isolated from diverse sources. *3 Biotech*, 11(6), Article 270. <https://doi.org/10.1007/s13205-021-02765-0>
- Kirtishanti, A., Wijono, H., Kok, T., Setiawan, E., Tanggo, V. V. C. M., Zahara, G. S., Davina, W., & Presley, B. (2025). Effect of multi-strain probiotic supplementation on chemotherapy-related side effects among patients with breast cancer: A pilot trial. *Pharmacia*, 72(1), 1–9. <https://doi.org/10.3897/pharmacia.72.e144998>

- Liu, Y., Sheng, Y., Pan, Q., Xue, Y., Yu, L., Tian, F., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. (2020). Identification of the key physiological characteristics of *Lactobacillus plantarum* strains for ulcerative colitis alleviation. *Food & Function*, 11(2), 1279–1291. <https://doi.org/10.1039/C9FO02935D>
- Matsuda, K., Tsuji, H., Asahara, T., Matsumoto, K., Takada, T., & Nomoto, K. (2009). Establishment of an analytical system for the human fecal microbiota, based on reverse transcription–quantitative PCR targeting of multicopy rRNA molecules. *Applied and Environmental Microbiology*, 75(7), 1961–1969. <https://doi.org/10.1128/AEM.01843-08>
- Matsuki, T., Watanabe, K., Fujimoto, J., Miyamoto, Y., Takada, T., Matsumoto, K., Oyaizu, H., & Tanaka, R. (2002). Development of 16S rRNA–gene–targeted group-specific primers for the detection and identification of predominant bacteria in human feces. *Applied and Environmental Microbiology*, 68(11), 5445–5451. <https://doi.org/10.1128/AEM.68.11.5445-5451.2002>
- Matsuki, T., Watanabe, K., Tanaka, R., Fukuda, M., & Oyaizu, H. (1999). Distribution of Bifidobacterial Species in Human Intestinal Microflora Examined with 16S rRNA-Gene-Targeted Species-Specific Primers. *Applied and Environmental Microbiology*, 65(10), 4506–4512. <https://doi.org/10.1128/aem.65.10.4506-4512.1999>
- Miller, R.A., Jian, J., Beno, S.M., Wiedmann, M., & Kovac, J. (2016). *Bacillus wiedmannii* sp. nov., a psychrotolerant and cytotoxic *Bacillus cereus* group species. *International Journal of Systematic and Evolutionary Microbiology*, 66(10), 4744–4753. <https://doi.org/10.1099/ijsem.0.001386>
- Moreno-Villares, J.M., Andrade-Platas, D., Soria-López, M., Colomé-Rivero, G., Catalán-Lambán, A., Martínez-Figueroa, M.G., Espadaler-Mazo, J., & Valverde-Molina, J. (2024). Comparative efficacy of *Bifidobacterium longum* KABP042 plus *Pediococcus pentosaceus* KABP041 versus *Limosilactobacillus reuteri* DSM17938 in infantile colic management: A randomized clinical trial. *European Journal of Pediatrics*, 183, 5371–5381. <https://doi.org/10.1007/s00431-024-05806-x>
- Nyotohadi, D., & Kok, T. (2023). Potential of multi-strain probiotics extract as an anti-inflammatory agent through inhibition of macrophage migration inhibitory factor activity. *Frontiers in Food & Health Discovery*, 13(1), 1–10. <https://doi.org/10.31989/ffhd.v13i1.1033>
- Nwamaioha, N. O., & Ibrahim, S. A. (2018, April 5). A selective medium for the enumeration and differentiation of *Lactobacillus delbrueckii* ssp. *bulgaricus*. *Journal of Dairy Science*, 101(6), 4953–4961. <https://doi.org/10.3168/jds.2017-14155>
- Santas, J.C., et al. (2015). *Pediococcus pentosaceus* CECT8330 and *Bifidobacterium longum* CECT7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. *International Journal of Pharmaceutical and Biological Sciences*, 6(2), 171–176.
- Simpson, P. J., Fitzgerald, G. F., Stanton, C., & Ross, R. P. (2006). Enumeration and identification of pediococci in powder-based products using selective media and rapid PFGE. *Journal of Microbiological Methods*, 64(1), 120–125. <https://doi.org/10.1016/j.mimet.2005.04.019>
- Tjandrawinata, R. R., Kartawijaya, M., Hartanti, A. W., & Hadianata, R. (2023). Characterization of in vitro antagonistic activity of *Lactobacillus helveticus* DLBSA201 and DLBSA202 against *Escherichia coli* O157:H7. *Food Science and Technology*, 43, e129522. <https://doi.org/10.5327/fst.129522>

- Tjandrawinata, R. R., Kartawijaya, M., Hartanti, A. W., & Hadianata, R. (2023). Characterization of in vitro antagonistic activity of *Lactobacillus helveticus* DLBSA201 and DLBSA202 against *Escherichia coli* O157:H7. *Food Science and Technology (Campinas)*, 43, e129522. <https://doi.org/10.1590/fst.129522>
- Tuomola, E. M., Crittenden, R., Playne, M., Isolauri, E., & Salminen, S. (2001). Quality assurance criteria for probiotic bacteria. *The American Journal of Clinical Nutrition*, 73(2 Suppl), 393S–398S. <https://doi.org/10.1093/ajcn/73.2.393s>
- Watanabe, K. September 1998. Primers for *Lactobacillus*. Japan patent application 1998-260041, publication 1999-151097
- Wu, R. Y., et al. (2019). Establishment of epithelial barrier and gut microbiota modulated by *Lactobacillus rhamnosus* GG in early life. *Scientific Reports*, 9, 10334. <https://doi.org/10.1038/s41598-019-46640-0>
- Xiao, F., Dong, F., Li, X., Li, Y., Yu, G., Liu, Z., Wang, Y., & Zhang, T. (2022). *Bifidobacterium longum* CECT 7894 improves the efficacy of infliximab for DSS-induced colitis via regulating the gut microbiota and bile acid metabolism. *Frontiers in Pharmacology*, 13, Article 902337. <https://doi.org/10.3389/fphar.2022.902337>
- Yang, Y., Zheng, L., et al. (2018). *Bifidobacterium breve* CCFM683 ameliorates DSS-induced colitis in mice primarily via conjugated linoleic acid production and gut microbiota modulation. *Frontiers in Microbiology*, 9, 2434. <https://doi.org/10.1016/j.jff.2018.08.014>
- Yu, J., Wang, H. M., Zha, M. S., Qing, Y. T., Bai, N., Ren, Y., et al. (2015). Molecular identification and quantification of lactic acid bacteria in traditional fermented dairy foods of Russia. *Journal of Dairy Science*, 98(8), 5143–5154. <https://doi.org/10.3168/jds.2015-9460>
- Zhang, C., Yang, L., Ding, Z., Yin, B., Chen, D., Guan, C., & Gu, R. (2019). New selective media for isolation and enumeration of *Lactobacillus rhamnosus* and *Streptococcus thermophilus*. *Journal of Food Measurement and Characterization*, 13(2), 1431–1439. <https://doi.org/10.1007/s11694-019-00059-x>

Culture Method



UNIVERSITAS GADJAH MADA

Bakteri	Selective Medium	Suhu	Durasi 28 ⁿ kubasi	Sumber
<i>Bacillus wiedmannii</i>	BHI, Nutrient Agar, Columbia Blood Agar	30 °C	24 jam	Miller et al., 2016
<i>Bifidobacterium breve</i>	Bifidobacterium selective medium + BSM suplemen	37 °C	24–48 jam	Chen et al., 2020; Chen et al., 2024; Yang et al., 2018
<i>Lactobacillus plantarum</i>	LPSM	30–37 °C	24–48 jam	Bujalance et al., 2006
<i>Lactobacillus rhamnosus</i>	MRS without glucose	37 °C	36–48 jam	Zhang et al., 2019
<i>Lactobacillus casei</i>	MMV (maltose-MRS-Vancomycin)	37 °C	48–72 jam	Lena et al., 2015
<i>Lactobacillus helveticus</i>	MRS	37 °C	24–48 jam	Griffiths and Tellez, 2013
<i>Lactobacillus fermentum</i>	MRS	37 °C	24–48 jam	-
<i>Lactobacillus bulgaricus</i>	Modified Reinforced Clostridial Medium (mRCM)	42 °C	12–24 jam	Nwamaioha et al., 2018
<i>Bifidobacterium longum</i>	Bifidobacterium selective medium + BSM suplemen	37 °C	24–48 jam	Hidalgo-Cantabrana et al., 2014
<i>Pediococcus pentosaceus</i>	Pediococci selective medium (PSM)	37 °C	24–48 jam	Simpson et al., 2006
<i>Rhodopseudomonas palustris</i>	RHODOSPIRILLACEAE MEDIUM (modified) (DSMZ Medium 27)	28 °C	48–72 jam	https://bacdiv.dsmz.de/strain/1819

Protokol qPCR



UNIVERSITAS GADJAH MADA

Bakteri	Primer (F / R)	Protokol qPCR	Sumber
<i>Lactobacillus casei</i>	sg-Lcas-F: ACCGCATGGTTCTTGGC sg-Lcas-R: CCGACAACAGTTACTCTGCC	Annealing 55 °C	Matsuda et al., 2009
<i>Lactobacillus plantarum</i>	sg-Lpla-F: CTCTGGTATTGATTGGTGCTTGCAT sg-Lpla-R: GTTCGCCACTCACTCAAATGTAAA	Annealing 60 °C	Matsuda et al., 2009
<i>Lactobacillus fermentum</i>	LFer-1: CCTGATTGATTTTGGTCGCCAAC LFer-2: ACGTATGAACAGTTACTCTCATACGT	Annealing 55 °C	Watanabe, K., 1998
<i>Lactobacillus helveticus</i>	Lh-R: CCAGGTGGTCGTGCTCTTAA Lh-F: TGACCGATCCGATCACTCTT	Annealing 57 °C	Yu et al., 2015
<i>Pediococcus pentosaceus</i>	-	-	-
<i>Bifidobacterium spp.</i>	G-Bifid-F: CTCCTGGAAACGGGTGG G-Bifid-R: ACATCTATAGCCCTTCTTGTGG	Annealing 55 °C	Matsuki et al., 2002
<i>Bifidobacterium breve</i>	BiBRE F: CCGGATGCTCCATCACAC BiBRE R: ACAAAGTGCCTTGCTCCCT	Annealing 55 °C	Matsuki et al., 1999
<i>Bifidobacterium longum</i>	BiLON F: TTCCAGTTGATCGCATGGTC BiLON R: GGGAAGCCGTATCTCTACGA	Annealing 55 °C	Matsuki et al., 1999
<i>Rhodopseudomonas palustris</i>	F: GCGGGAAGATAATGACGGT R: TGGTAGCAACTAAGGACGG	Annealing 65 °C	CN Patent CN101195841A, 2008
<i>Lactobacillus rhamnosus</i>	sg-Lcas-F: ACCGCATGGTTCTTGGC sg-Lcas-R: CCGACAACAGTTACTCTGCC	Annealing 55 °C	Matsuda et al., 2009

Publikasi terkait strain



UNIVERSITAS GADJAH MADA

Bacillus wiedmannii

Bakteri	Asal Isolat	Sifat Fisiologis & Genetik	Aktivitas / Potensi Biologis	Pustaka
<i>Bacillus wiedmannii</i> FSL W8-0169T	Susu mentah (USA, 2012)	Genom 5.3 Mb, G+C 35.3%, tidak memfermentasi sukrosa & arginin, MLST baru, rpoB AT 61	- Sitotoksik terhadap sel HeLa - Menghasilkan enterotoksin HBL dan NHE - Psikrotoleran, tumbuh pada 7°C	Miller et al., 2016
<i>Bacillus wiedmannii</i> FSL H7-0353	Produk susu siap konsumsi (2005)	Genom 5.6 Mb, rpoB AT 61	- Sitotoksik (mirip W8-0169T) - Potensial patogen makanan	Miller et al., 2016
<i>Bacillus wiedmannii</i> FSL H8-0032	Produk susu siap konsumsi (2005)	Genom 5.6 Mb, profil MLST baru	Tidak dijelaskan spesifik, diasumsikan serupa dalam kelompok <i>B. wiedmannii</i>	Miller et al., 2016
<i>Bacillus wiedmannii</i> FSL J3-0113	Produk susu (2012)	Genom 5.6 Mb, rpoB AT 417	Tidak dijelaskan rinci, termasuk dalam kelompok sitotoksik dan psikrotoleran	Miller et al., 2016
<i>Bacillus wiedmannii</i> (unspecified)	Tidak disebutkan	Mengandung gen bawA, tidak memiliki sekuens leader (<i>leaderless bacteriocin</i>)	- Memproduksi bacteriocin Bawcin - Spektrum antibakteri luas terhadap <i>Listeria monocytogenes</i>, <i>B. subtilis</i>, <i>Lactococcus lactis</i>, dll	Budhwani et al., 2023

Bifidobacterium breve CCFM683

No	Model	Treatment	Dose & Duration	Parameters Analyzed	Conclusion	Source
1	Mouse (IMQ-induced psoriasis)	Oral gavage of <i>B. breve</i> CCFM683	1×10^9 CFU/day for 6 days	PASI score, ear thickness, cytokines (IL-17, TNF- α , IL-10), FXR-TLR4/NF- κ B signaling, gut microbiota, bile acids	CCFM683 ameliorates psoriasis via microbiota modulation, increased DCA/LCA, and inhibition of inflammatory pathways	Chen et al., 2024
2	Mouse (IMQ-induced psoriasis)	Oral <i>B. breve</i> CCFM683 at multiple doses	10^6 - 10^{10} CFU/day for 6 days	PASI score, histology, cytokines, bile acids, gene expression (K16, K17, involucrin)	Dose-dependent relief; optimal at $\geq 10^{8.42}$ CFU/day; improved skin barrier, reduced inflammation via FXR/NF- κ B	Chen et al., 2023
3	Mouse (DSS-induced colitis)	Oral gavage <i>B. breve</i> CCFM683	1×10^9 CFU/day for 7 days before and during DSS	DAI, colon length, MPO, cytokines (IL-10, IL-6, TNF- α), PPAR γ , gut microbiota, colonic CLA	Ameliorates colitis via CLA production, microbiota modulation, and anti-inflammatory effects	Yang et al., 2018
4	Mouse (ApcMin/+ colorectal tumor model)	Oral <i>B. breve</i> CCFM683	10^9 CFU/day for 8 weeks	Tumor number, gut microbiota, bile acids, gene expression (FXR, TLR4, NF- κ B), CLA	Inhibits tumorigenesis via CLA, microbiota regulation, bile acid modulation, suppressed inflammation	Chen et al., 2025
5	In vitro & metabolomics	Linoleic acid induction in two <i>B. breve</i> strains (CCFM683 and CCFM1025)	Exposure to LA in culture	Intracellular metabolites, PCA, metabolic fluxes	<i>B. breve</i> CCFM683 shows different metabolic modes and higher CLA production in response to LA	Gao et al., 2021

Publikasi terkait strain



UNIVERSITAS GADJAH MADA

***L. plantarum* N13**

Bakteri	Asal / Koleksi	Penggunaan	Ciri Fisiologis Utama	Model Uji	Parameter yang Dianalisis	Hasil Utama	Pustaka
<i>Lactobacillus plantarum</i> N13	Susu fermentasi	Tunggal	Produksi CLA tinggi, toleransi asam & empedu, adhesi tinggi ke sel HT-29	DSS-induced colitis pada tikus BALB/c	DAI, panjang kolon, sitokin (IL-6, TNF- α), mikrobiota usus	Menurunkan gejala kolitis, ekspresi IL-6 dan TNF- α turun, mikrobiota kembali seimbang	Liu et al., 2024

***L. rhamnosus* CCFM1064** – belum ada publikasi

***L. casei* CCFM8441** – belum ada publikasi

Publikasi terkait strain



UNIVERSITAS GADJAH MADA

Lactobacillus helveticus strain DLBSA201 dan DLBSA202

Bakteri	Media & Kondisi Kultur	Model Uji	Parameter yang Dianalisis	Hasil (Individu)	Hasil (Kombinasi dengan DLBSA202)	Pustaka
<i>L. helveticus</i> DLBSA201	MRS HiVeg broth, 37°C, 18–22 jam	In vitro (pH, empedu, Caco-2, E. coli O157:H7, ekspresi gen)	Toleransi asam (pH 3)	Viabilitas 56%	–	Tjandrawinata et al., 2023
			Toleransi empedu (0.5%)	Viabilitas >97%	–	
			Aktivitas BSH	Tidak ada aktivitas	–	
			Adhesi ke sel Caco-2	89% sel bakteri melekat	–	
			Hambatan E. coli O157:H7 (agar difusi)	Zona hambat 12 mm	Zona hambat 15 mm	
			Hambatan pertumbuhan E. coli dalam CFS	Penurunan ±15%	Penurunan ±30%	
			Displacement di sel Caco-2	Tidak signifikan	Signifikan menurunkan kolonisasi E. coli	
			Ekspresi TLR-4, IL-8	Tidak signifikan	Menurun signifikan	
			Ekspresi TNF-α	Tidak signifikan	Menurun signifikan	
			Ekspresi occludin & ZO-1	Tidak signifikan	Meningkat signifikan	
			Ekspresi claudin-2	Tidak signifikan	Tren penurunan ($p \approx 0.09$)	

Publikasi terkait strain



UNIVERSITAS GADJAH MADA

Bifidobacterium longum CECT 7894 dan *Pediococcus pentosaceus* CECT 8330

Bakteri	Model Uji	Dosis & Durasi	Media & Kondisi Kultur	Parameter yang Dianalisis	Hasil Ringkasan	Pustaka
<i>Bifidobacterium longum</i> CECT 7894	DSS-induced colitis, tikus C57BL/6	5×10^8 CFU/hari, 5 hari	MRS anaerobik 37 °C	DAI, panjang kolon, ekspresi ZO-1, occludin, histologi kolon	Menurunkan DAI, memperbaiki kolon, ekspresi tight junction meningkat	Xiao et al., 2022
<i>Pediococcus pentosaceus</i> CECT 8330	DSS-induced colitis, tikus C57BL/6	5×10^8 CFU/hari, 5 hari	MRS mikroaerofilik (5% CO ₂), 37 °C	DAI, CMDI, sitokin (TNF- α , IL-1 β , IL-6, IL-10), Treg, ZO-1, occludin, SCFA, microbiota	Mengurangi inflamasi, meningkatkan IL-10 & Treg, meningkatkan SCFA, memperbaiki microbiota	Dong et al., 2022
<i>B. longum</i> CECT 7894 + <i>P. pentosaceus</i> CECT 8330	Uji klinis bayi kolik (Chen et al.)	1×10^9 CFU/hari, 21 hari	Probiotik oral suspensi klinis	Durasi dan frekuensi menangis, konsistensi tinja, frekuensi buang air besar, rasio respon klinis	Durasi menangis menurun signifikan dari hari ke-7, 14, 21; perbaikan tinja & kenyamanan gastrointestinal bayi	Chen et al., 2021
<i>B. longum</i> CECT 7894 + <i>P. pentosaceus</i> CECT 8330	Uji klinis pilot bayi kolik (Santas et al.)	1×10^9 CFU/hari, 21 hari	Tidak dilaporkan rinci (oral probiotik)	Durasi menangis, konsistensi tinja	Penurunan durasi menangis (81 $\rightarrow$ 54 min/hari); tren membaik tapi tidak signifikan (P=0.083)	Santas et al., 2015

Publikasi terkait strain



UNIVERSITAS GADJAH MADA

Multistrain EMRO

Strain Kombinasi	Model Uji	Metode Uji & Media Kultur	Parameter yang Dianalisis	Hasil Utama	Pustaka
<i>Rhodopseudomonas palustris</i> EMRO201 <i>Lactobacillus casei</i> EMRO002 <i>Lactobacillus casei</i> EMRO213 <i>Lactobacillus plantarum</i> EMRO009 <i>Lactobacillus fermentum</i> EMRO211 <i>Lactobacillus bulgaricus</i> EMRO212 <i>Lactobacillus rhamnosus</i> EMRO014	In vitro enzyme assay pada enzim inflamasi MIF (Macrophage Migration Inhibitory Factor)	- Medium fermentasi: madu (1.13%), asam sitrat (20mg/mL), molases (3.07%), aloe vera (1.07%)- Fermentasi selama 45 hari, kondisi anaerob, suhu 26 °C - Hasil: supernatan dengan total populasi $\sim 2 \times 10^6$ CFU/mL per strain - Uji kinetik enzim MIF tautomerase: metode spektrofotometri dengan atau tanpa preincubation dan dilusi	- IC₅₀ (konsentrasi penghambat 50%)- Mode inhibisi (kompetitif / nonkompetitif) - Efek reversibilitas terhadap enzim	- IC₅₀ = 7.80 ± 1.96 mg/L- Efek penghambatan reversibel terhadap enzim MIF - Dugaan mekanisme non-kompetitif (allosterik site)	Nyotohadi & Kok, 2023
<i>Rhodopseudomonas palustris</i> EMRO201 <i>Lactobacillus casei</i> EMRO002 <i>Lactobacillus casei</i> EMRO213 <i>Lactobacillus plantarum</i> EMRO009 <i>Lactobacillus fermentum</i> EMRO211 <i>Lactobacillus bulgaricus</i> EMRO212 <i>Lactobacillus rhamnosus</i> EMRO014	Uji klinis pada manusia (pilot trial) – pasien kanker payudara stadium lanjut yang sedang menjalani kemoterapi aktif	- Subjek: pasien kanker payudara stadium lanjut yang sedang menjalani kemoterapi- Intervensi: PRO EM1 cair, diminum 3x/hari (7.5–15 mL per kali) - Durasi: 21–30 hari- Total kandungan probiotik: $> 2 \times 10^6$ CFU/mL per strain - Monitoring klinis: fungsi ginjal, hati, kondisi fungsional, dan gejala terkait kemoterapi	- <i>Karnofsky Performance Score</i> - Gejala: kelelahan, mual- BUN, kreatinin, ALT, HIT count	- <i>Karnofsky Score</i> meningkat signifikan (dari 90 ke 100; $p < 0.001$) - BUN menurun signifikan ($p = 0.008$)- Gejala mual & kelelahan membaik- ALT, kreatinin, HIT stabil (tidak toksik)	Kirtishanti et al., 2025